March 14, 2016
By Shreeya Nanda
Addition (click here) of lapatinib (Tyverb) to trastuzumab (Herciptin) improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
The findings of the EPHOS-B trial were presented at the 10th European Breast Cancer Conference (EBCC-10) in Amsterdam, the Netherlands, by Judith Bliss, from The Institute of Cancer Research in London, UK....
These two drugs administered together have destroyed the cancer cells. The initial study was successful in 11 percent of the cases. Those are 11 percent of women able to live to be a wife, mother and contribute to our world in a career.
From the MAYO Clinic
By Timothy J. Moynihan
HER2-positive breast cancer (click here) is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. They're less likely to be sensitive to hormone therapy, though many people with HER2-positive breast cancer can still benefit from hormone therapy.
Treatments that specifically target HER2 are very effective. These treatments are so effective that the prognosis for HER2-positive breast cancer is actually quite good.
Treatments include:
By Shreeya Nanda
Addition (click here) of lapatinib (Tyverb) to trastuzumab (Herciptin) improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
The findings of the EPHOS-B trial were presented at the 10th European Breast Cancer Conference (EBCC-10) in Amsterdam, the Netherlands, by Judith Bliss, from The Institute of Cancer Research in London, UK....
These two drugs administered together have destroyed the cancer cells. The initial study was successful in 11 percent of the cases. Those are 11 percent of women able to live to be a wife, mother and contribute to our world in a career.
From the MAYO Clinic
By Timothy J. Moynihan
HER2-positive breast cancer (click here) is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. They're less likely to be sensitive to hormone therapy, though many people with HER2-positive breast cancer can still benefit from hormone therapy.
Treatments that specifically target HER2 are very effective. These treatments are so effective that the prognosis for HER2-positive breast cancer is actually quite good.
Treatments include:
- Trastuzumab (Herceptin)
- Lapatinib (Tykerb)
- Pertuzumab (Perjeta)
- Ado-trastuzumab emtansine (Kadcyla)
